| Product Code: ETC8887516 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The market for large molecule drug substance CDMO import shipments in Portugal saw a significant increase in concentration in 2024, with the top exporting countries being the Netherlands, Spain, USA, Sweden, and UK. The Herfindahl-Hirschman Index (HHI) indicates very high concentration levels, reflecting a competitive landscape dominated by a few key players. Despite a remarkable compound annual growth rate (CAGR) of 56.26% from 2020 to 2024, there was a slight decline in growth from 2023 to 2024. This data suggests a dynamic market environment with strong potential for further developments and strategic opportunities.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Portugal Large Molecule Drug Substance CDMO Market Overview |
3.1 Portugal Country Macro Economic Indicators |
3.2 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Portugal Large Molecule Drug Substance CDMO Market - Industry Life Cycle |
3.4 Portugal Large Molecule Drug Substance CDMO Market - Porter's Five Forces |
3.5 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.6 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.7 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Portugal Large Molecule Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for large molecule drugs globally |
4.2.2 Rise in outsourcing of drug substance manufacturing to CDMOs |
4.2.3 Growing focus on personalized medicine and biologics |
4.2.4 Technological advancements in large molecule drug development and manufacturing |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and compliance standards |
4.3.2 High initial investment and operating costs for CDMOs |
4.3.3 Intense competition among CDMOs in the market |
4.3.4 Risks associated with intellectual property protection and confidentiality |
5 Portugal Large Molecule Drug Substance CDMO Market Trends |
6 Portugal Large Molecule Drug Substance CDMO Market, By Types |
6.1 Portugal Large Molecule Drug Substance CDMO Market, By Service |
6.1.1 Overview and Analysis |
6.1.2 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Service, 2021- 2031F |
6.1.3 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F |
6.1.4 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.1.5 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021- 2031F |
6.1.6 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F |
6.1.7 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Cell Line Development, 2021- 2031F |
6.1.8 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021- 2031F |
6.2 Portugal Large Molecule Drug Substance CDMO Market, By Source |
6.2.1 Overview and Analysis |
6.2.2 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Mammalian, 2021- 2031F |
6.2.3 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Microbial, 2021- 2031F |
6.2.4 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Portugal Large Molecule Drug Substance CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.3.3 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By CRO, 2021- 2031F |
6.3.4 Portugal Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 Portugal Large Molecule Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Portugal Large Molecule Drug Substance CDMO Market Export to Major Countries |
7.2 Portugal Large Molecule Drug Substance CDMO Market Imports from Major Countries |
8 Portugal Large Molecule Drug Substance CDMO Market Key Performance Indicators |
8.1 Capacity utilization rate of CDMOs |
8.2 Number of new partnerships and collaborations in the market |
8.3 Time to market for large molecule drug substances |
8.4 Rate of successful technology transfers |
8.5 Customer satisfaction and retention rates |
9 Portugal Large Molecule Drug Substance CDMO Market - Opportunity Assessment |
9.1 Portugal Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.2 Portugal Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Source, 2021 & 2031F |
9.3 Portugal Large Molecule Drug Substance CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 Portugal Large Molecule Drug Substance CDMO Market - Competitive Landscape |
10.1 Portugal Large Molecule Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Portugal Large Molecule Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |